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Abstract 
Introduction: Multidrug resistance in Pseudomonas aeruginosa may be due to efflux pump overexpression. This study phenotypically examined 
the role of efflux pump inhibitors in decreasing antibiotic cross-resistance between beta-lactams, fluoroquinolones, and aminoglycosides in P. 
aeruginosa isolates from burn patients in Iran. 
Methodology: A total of 91 phenotypically and genotypically confirmed P. aeruginosa samples were studied. Multidrug cross-resistance was 
determined using the disk diffusion method and minimum inhibitory concentration (MIC) test. The contribution of efflux pumps was 
determined by investigating MIC reduction assay to markers of beta-lactams, fluoroquinolones, and aminoglycosides in the absence and 
presence of an efflux pump inhibitor. All the isolates were also tested by polymerase chain reaction for the presence of mexA, mexC, and mexE 
efflux genes. 
Results: Of the isolates, 81 (89%) and 83 (91.2%) were multidrug resistant according to the disk diffusion and MIC method, respectively. 
Cross-resistance was observed in 67 (73.6%) and 68 (74.7%) of isolates according to the disk diffusion and MIC method, respectively. In the 
presence of the efflux pump inhibitor, twofold or higher MIC reduction to imipenem, cefepime, ciprofloxacin, and gentamicin was observed 
in 59, 65, 55, and 60 isolates, respectively. Except for two isolates that were negative for mexC, all isolates were positive for mexA, mexC, and 
mexE genes simultaneously. 
Conclusion: Efflux pumps could cause different levels of resistance based on their expression in clinical isolates. Early detection of different 
efflux pumps in P. aeruginosa could allow the use of other antibiotics and efflux pump inhibitors in combination with antibiotic therapy. 
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Introduction 
Pseudomonas aeruginosa is an opportunistic 
pathogen that causes a variety of infections, especially 
in immunocompromised patients such as burn patients. 
Infections caused by P. aeruginosa are related to 
significant morbidity and mortality [1,2]. The organism 
exhibits a high level of intrinsic resistance and only a 
limited number of antimicrobial agents are active 
against it [3]. In addition, P. aeruginosa has a 
remarkable ability to acquire further resistance 
mechanisms to multiple groups of antimicrobial agents, 
including beta-lactams, aminoglycosides, and 
fluoroquinolones [4]. P. aeruginosa represents a 
phenomenon of bacterial resistance, since practically all 
known mechanisms of antimicrobial resistance, 
including import of resistance mechanisms on mobile 
genetic elements, the chromosomally encoded AmpC 
cephalosporinase, the outer membrane porin OprD, and 
the multidrug efflux pumps can be seen in it [5,6]. 
Among these resistance mechanisms, overexpression of 
efflux systems has been implicated in multidrug-
resistant phenotypes in P. aeruginosa clinical isolates 
[7]. Beta-lactams, fluoroquinolones, and 
aminoglycosides are three important substrates of 
efflux pumps which could be overexpressed in P. 
aeruginosa strains. To recognize the presence of 
acquired multidrug resistance due to efflux pump 
overexpression, phenotypic and genotypic tests may be 
used in laboratory practice [3]. Increased expression of 
efflux pumps could increase the minimum inhibitory 
concentrations (MICs) of antimicrobials agents [3]. A 
series of different compounds have been identified as 
efflux pump inhibitors with the ability to broadly inhibit 
several identified multidrug efflux pumps in P. 
aeruginosa [6]. In this study, multidrug resistance due 
to overexpression of the efflux systems was evaluated 
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by phenotypic tests in the presence of carbonyl cyanide 
3-chlorophenylhydrazone (CCCP) as an efflux pump 
inhibitor. CCCP is a known proton motive force and 
efflux pump inhibitor [8] that can be added in Mueller-
Hinton agar during its preparation. The MICs of 
antibiotics for strains overexpressing efflux pumps are 
usually twofold or higher than those strains of species 
that do not overexpress efflux pumps. This phenotypic 
test is a valuable method to detect efflux pump 
overexpression that contributes to multidrug cross-
resistance among bacteria. We hypothesized that part of 
the antibiotic resistance among P. aeruginosa isolates 
could be due to overexpression of efflux pumps. We 
used CCCP as a screening agent to assess (i) the 
prevalence of efflux pump overexpression among 
multidrug-resistant isolates of P. aeruginosa; (ii) the 
contribution of efflux pump overexpression as the 
supposed mechanism for the multidrug cross-resistance 
between beta-lactams, fluoroquinolones, and 
aminoglycosides in P. aeruginosa; and (iii) MIC 
reduction of beta-lactams, fluoroquinolones, and 
aminoglycosides simultaneously in the presence of an 




The study included a total of 91 P. aeruginosa 
isolates recovered consecutively from burn wound 
infections of patients hospitalized at a burn hospital in 
Tehran, Iran. P. aeruginosa isolates were first identified 
based on standard biochemical tests [9]. Then 
phenotypic identification was confirmed at the species 
level by using polymerase chain reaction (PCR) 
amplification of oprI and oprL genes [10] (Table 1). 
Bacterial genomic DNA was extracted by the boiling 
method. For this purpose, all isolates were inoculated 
aerobically on nutrient agar (Merck, Darmstadt, 
Germany) for 18–24 hours at 37°C. Depending on 
colony size, three to six colonies were picked from 
plates and mixed in 0.1 mL DNase/RNase-free water in 
sterile 1.5 mL tubes to obtain a turbid suspension of 
bacteria (~1–2×109 cells/mL). The cell suspensions 
were held in a boiling water bath for 10 minutes to lyse 
the cells and then centrifuged at 10,000 g at 4°C for 10 
minutes. Then in sterile conditions, the supernatant 
liquid was transferred into another tube. The tubes were 
stored at -20°C prior to being used in PCR amplification 
as a DNA template. Also, all the confirmed P. 
aeruginosa isolates were stored at -70°C in trypticase 
soy broth (Merck, Darmstadt, Germany) supplemented 
with 10% glycerol until ready for further experiments. 
Control strains included PAO1 (wild type) and P. 
aeruginosa ATCC 27853 [11]. 
 
In vitro susceptibility testing 
Antibiotic susceptibility testing of P. aeruginosa 
species was done using the disk diffusion method on 
Mueller-Hinton agar (Merck, Darmstadt, Germany). 
All isolates were tested for susceptibility to imipenem 
(10 μg), cefepime (30 μg), ticarcillin (75 μg), aztreonam 
(30 μg), tobramycin (10 μg), gentamicin (10 μg), 
colistin (25 μg), amikacin (30 μg), ciprofloxacin (5 μg), 
piperacillin (100 μg), and piperacillin-tazobactam (110 
μg) (Mast, Merseyside, UK). All isolates were then 
subjected to determination of MICs for imipenem 
(Sigma-Aldrich, Stelnhelm, Germany) and cefepime 
(Sigma-Aldrich, Stelnhelm, Germany) as markers of 
beta-lactams, ciprofloxacin (Sigma-Aldrich, Stelnhelm, 
Germany) as a marker of fluoroquinolones, and 
gentamicin (Sigma-Aldrich, Stelnhelm, Germany) as a 
marker of aminoglycosides. Isolates showing resistance 
to one or more antibiotics from three or more 
antimicrobial classes were considered to be multidrug 
resistant. Since the efflux pump inhibitors could reduce 
the MICs required to kill the resistant organisms, the 
MIC analyses of the mentioned antibiotics were 
performed again in the presence of CCCP (Sigma-
Aldrich, St. Louis, USA), for all resistant strains. CCCP 
was incorporated in Mueller-Hinton agar (Merck, 
Darmstadt, Germany) at concentrations of 12.5 μM, and 
Table 1. Primers used in this study. 
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MIC reduction testing was performed by the twofold 
serial dilution method using a final inoculum of 106 
cells/mL in agar plates with CCCP [12]. P. aeruginosa 
ATCC 27853 and PAO1 were used as reference strains. 
Both methods were carried out and interpreted 
according to the guidelines established by the Clinical 
and Laboratory Standards Institute (CLSI; M100-S24, 
2014). The second MIC tests were performed to check 
the role of efflux pumps in resistance to beta-lactams, 
fluoroquinolones, and aminoglycosides. These 
antibiotics selectively extracted by different efflux 
systems in pseudomonads [13]. 
 
PCR for mexA, mexC, and mexE genes 
To investigate the presence of different efflux 
genes, all the isolates were tested by PCR for the 
presence of mexA, mexC, and mexE genes, which are 
representative of MexAB-OprM, MexCD-OprJ, and 
MexEF-OprN efflux systems, respectively, using 
previously described primers [12,14]. Primer 
designations and their sequences are shown in Table 1. 
 
Results 
A total of 91 strains of P. aeruginosa were isolated 
from wound infections of hospitalized burn patients and 
confirmed using biochemical tests and confirmatory 
PCR assays. The results of the disk diffusion 
antibiogram showed that 81 (89%) of the P. aeruginosa 
isolates exhibited resistance to three or more antibiotics. 
According to the antibiogram results, aside from 
colistin, to which all the isolates were susceptible, the 
highest rate of resistance was seen against imipenem 
and tobramycin (88%) and the lowest rate of resistance 
was seen against aztreonam (76%). According to the 
disk diffusion method, 81 (89%) isolates were 
multidrug resistant, of which 67 (83%) isolates were 
resistant to imipenem, cefepime, ciprofloxacin, and 
gentamicin simultaneously. Figure 1 summarizes the 
susceptibility status of isolates against 11 studied 
antibiotics according to the disk diffusion method. MIC 
reduction tests to markers of beta-lactams, 
fluoroquinolones, and aminoglycosides were done in 
the absence (as control) and presence of CCCP. 
Table 2. Distribution of isolates by level of resistance to tested antibiotics in the absence/presence of carbonyl cyanide 3-
chlorophenylhydrazone (CCCP). The number of resistant isolate according to Clinical and Laboratory Standards Institute breakpoints are 
shown in bold. 
Antibiotic ≤ 0.5 μg/mL 1 μg/mL 2 μg/mL 4 μg/ml 8 μg/mL 16 μg/mL 32 μg/mL ≥ 64 μg/mL 
Imipenem 0 / 0 0 / 0 2 / 8 12 / 19 2 / 12 4 / 5 10 / 16 61 / 31 
Cefepime 0 / 0 0 / 0 0 / 10 13 / 14 1 / 4 1 / 1 1 / 4 75 / 58 
Ciprofloxacin 7 / 29 2 / 1 1 / 1 1 / 4 8 / 31 53 / 18 10 / 5 9 / 2 
Gentamicin 0 / 0 1 / 10 1 / 12 6 / 14 5 / 2 0 / 5 1 / 8 77 / 40 
 
 
Table 3. Role of carbonyl cyanide 3-chlorophenyl hydrazine (CCCP) in reduction of minimum inhibitory concentration (MIC) of antibiotics 
on resistant Pseudomonas aeruginosa. 
 Fold MIC reduction  




Imipenem (n = 77) 18 (24%) 33 (42%) 8 (10%) 4 (6%) 6 (8%) 8 (10%) 4 (4%) 
Cefepime (n = 76) 12 (16%) 25 (33%) 14 (19%) 8 (11%) 1 (1%) 15 (20%) 5 (6%) 
Ciprofloxacin (n = 81) 25 (31%) 28 (35%) 7 (9%) 1 (1%) 5 (6%) 15 (18%) 20 (24.5%) 
Gentamicin (n = 78) 23 (30%) 21 (27%) 7 (9%) 2 (3%) 2 (3%) 23 (28%) 24 (26%) 
 
Figure 1. Susceptibility status of the isolates against 11 studied 
antibiotics according to disk diffusion. IMI: imipenem; CEF: 
cefepime; TC: ticarcillin; AZ: aztreonam; TOB: tobramycin; 
GN: gentamicin; CO: colistin; AK: amikacin; CIP: 
ciprofloxacin; PTZ: piperacillin-tazobactam; PIP: piperacillin 
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According to CLSI guidlines, the P. aeruginosa isolates 
with MIC ≥ 8 mg/L, MIC ≥ 32 mg/L, MIC ≥ 4 mg/L, 
and MIC ≥ 16 mg/L are considered as imipenem, 
cefepime, ciprofloxacin, and gentamicin resistant, 
respectively. The preliminary results of the MIC 
method showed that 68 (75%) isolates were resistant to 
imipenem, cefepime, ciprofloxacin, and gentamicin 
simultaneously. Table 2 summarizes the distribution of 
studied isolates by level of resistance to the tested 
antibiotics. By comparing the MIC results, with and 
without CCCP, twofold or higher MIC reduction to 
imipenem, cefepime, ciprofloxacin, and gentamicin 
was observed in 59, 65, 55, and 60 isolates, 
respectively, out of 91 samples on the CCCP-
supplemented plate. Table 3 shows the role of CCCP in 
the reduction of MICs for the different antibiotic class 
markers. PCR revealed that, except for two isolates that 
were negative for mexC, all the isolates were positive 
for mexA, mexC, and mexE genes as representative of 
MexAB-OprM, MexCD-OprJ, and MexEF-OprN 
efflux systems, respectively. 
 
Discussion 
The incidence of infectious diseases with high 
ranges of antibiotic resistance in developing countries 
is on the rise. P. aeruginosa is an opportunistic Gram-
negative bacterium, resistant to multiple drugs. The 
organism exhibits a high level of intrinsic resistance and 
has also acquired multiple mechanisms of resistance to 
all available anti-pseudomonal agents [4]. The findings 
of the present study clearly show that antibiotic 
resistance rates are high among P. aeruginosa isolates 
in burn patients in Iran. Almost all isolates were 
resistant to three or more antibiotics tested except 
colistin, which showed the highest (100%) antibacterial 
activity. Only three (3.3%) P. aeruginosa isolates were 
fully susceptible. We observed a high rate of resistance 
to imipenem, cefepime, ciprofloxacin, and gentamicin 
as markers of beta-lactams, fluoroquinolones, and 
aminoglycosides, which are employed to treat P. 
aeruginosa infections. Most of the resistant P. 
aeruginosa isolates showed multidrug resistance to two 
or three tested antibiotic classes. We assumed that part 
of these multidrug cross-resistances among P. 
aeruginosa isolated from burn wound infections could 
be due to overexpression of multidrug efflux pumps, 
because efflux pumps have broad substrate specificity, 
and every efflux pump expels several antibiotic classes, 
including beta-lactams, quinolones, and 
aminoglycosides [12]. Widespread and improper use of 
antibiotics that are efflux pump substrates could be one 
of the main causes of inducing multidrug cross-
resistance among P. aeruginosa in burn wound 
infections. Also, we assumed that it could have an 
adverse collateral effect on the susceptibility of P. 
aeruginosa to other existing anti-pseudomonal agents 
and more incidence of multidrug efflux pumps 
overexpression. To further investigate this assumption, 
we used the broad-spectrum efflux pump inhibitor 
compound, CCCP, and phenotypically investigated the 
efflux pump overexpression in clinical isolates of P. 
aeruginosa. We used this method because the 
susceptibility of P. aeruginosa strains to antimicrobial 
agents can be significantly enhanced by pump 
inactivation [13]. According to our present 
observations, many clinical isolates of P. aeruginosa 
with a wide range of resistant phenotypes showed 
increased susceptibility to imipenem, cefepime, 
ciprofloxacin, and gentamicin as makers of beta-
lactams, fluoroquinolones, and aminoglycosides in the 
presence of efflux pump inhibitors. These results 
confirmed the simultaneous multidrug extrusion by the 
efflux systems. After adding CCCP, the accumulation 
of antibiotics increased and led to lower antibiotic 
MICs. Inhibition of efflux pumps by CCCP in some 
isolates brought MICs down even to the levels that 
make them sensitive strains of P. aeruginosa. 
Therefore, efflux pumps have an important role in the 
development multidrug-resistant P. aeruginosa isolates 
of burn patients in Iran. Based on genetic investigation 
to detect the presence of mexA, mexC, and mexE genes, 
we observed that, except for two isolates, the multidrug-
resistant strains had these genes simultaneously, while 
according to phenotypic investigation to detect the 
efflux pump overexpression, twofold or higher MIC 
reduction to imipenem, cefepime, ciprofloxacin, and 
gentamicin was observed in only about 50% of the 
isolates. One possible explanation is that some of the 
efflux pumps are inactive now and could be 
overexpressed later. A major beneficial consequence of 
inhibition of efflux pumps demonstrated in this study is 
the notable decrease in the frequency of emergence of 
P. aeruginosa strains with clinically relevant levels of 
resistance to different antibiotic classes; also, further 
studies on efflux pump inhibitors appear to be an 
attractive approach to improving the clinical efficacies 
of antibiotics that are substrates of these pumps [15]. 
Since some antibiotic classes are substrates for several 
prevalent efflux pumps in P. aeruginosa [16], we could 
decrease the resistance pattern among P. aeruginosa 
isolates by inhibiting efflux pumps in combination with 
antibiotic therapy. We should consider the prevalence 
of efflux-mediated resistance apart from the other 
known resistance mechanisms in P. aeruginosa 
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isolates. These compounds may be very useful to study 
the contribution and prevalence of efflux pumps in 
intrinsic and acquired resistance to multiple antibiotics 
in other Gram-negative bacteria. Our efforts were 
focused on the evaluation of CCCP in P. aeruginosa 
strains; we suggest further studies to analyze the role of 
efflux inhibitors in different bacterial resistance. 
 
Conclusions 
It seems that multidrug resistance to most 
therapeutic antibiotics is common in P. aeruginosa 
isolates from burn patients in Iran. Since we observed 
resistance to unrelated antibiotic classes, it should be 
considered that improper use of antibiotics could causes 
resistance to other classes by triggering the 
overexpression of efflux pumps and select for mutants 
with multidrug cross-resistance. Efflux pump inhibitors 
could ideally increase the effectiveness of antibiotics in 
multidrug-resistant P. aeruginosa isolates. 
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